SYDRA

Synergistic combination of 3 geroprotectors in C. elegans and their effect on healthspan and lifespan. The paper is in progress. Interested about the outcome?

Today, we at Lifespan.io pause to commemorate the extraordinary contributions of Dr. Leonard Hayflick, a true pioneer of aging research and a scientist of remarkable achievement. Dr. Hayflick's groundbreaking discovery of cellular senescence revolutionized our understanding of the aging process. This same work has also laid the groundwork for subsequent research on telomeres and their critical roles in aging and cancer. His influential book, “How and Why We Age,” offers an accessible exploration of the biological mechanisms behind aging and their implications for human health. Dr. Hayflick served as a professor at University of California, San Francisco School of Medicine and Stanford University School of Medicine. He was a past president of the Gerontological Society of America (GSA) and a founding member of the National Institute on Aging (NIA). His seminal work has been a cornerstone for research on the aging process, profoundly shaping our approaches to understanding human aging. We are proud to count ourselves as part of the effort that continues to bring aging research further and further into mainstream focus. Rest in peace.

A nematode species commonly used for aging research lives much longer on an alternate-day fasting regimen, but ✴️ only when it is administered in middle age and  ✴️ only when the worms are consuming an animal-based protein source https://lnkd.in/d5J_Z9wV by Josh Conway #longevity #lifespan #DietaryRestriction #DR #Celegans 

Recently Stuart Cook published impressive lifespan data on an unexplored pathway which is inhibition of an inflammation boosting protein called Interleukin-11 (pubmed: 39020175). The result was median lifespan extension by 25% in female mice and 23% in males. It will be very interesting to see other labs reproduce the results and also see what the maximum lifespan effect of this intervention will be. In a ARDD conference presentation Stuart showed a simplified overview of the proposed mechanism of actions behind why interleukin-11 inhibition works. I really like this simplified relation “ERK inhibition > AMPK activation > mTOR inhibition”. He also listed different pharmaceutical drugs which targeted each part. Again, keep in mind it’s a simplified relation but there is something elegant with it. Because it gives a framework to put some puzzle pieces together around what may be interesting potential combinational therapies. One week after Stuart had published his paper then Linda Partridge published a paper where they discovered impressive lifespan effect when Rapamycin, a mTOR inhibitor, and Trametinib, a MEK/ERK inhibitor was combined (doi: 10.1101/2024.07.25.605097). The result was median lifespan extension by 35% in female mice and 27% in males and maximum lifespan extension was 32% in females and 26% in males. This maps nicely with the simplified overview proposed by Stuart. There are two things that differ between the two studies. 1) The treatment in this study started in young mice and not old mice. 2) It was also a different strain of mice. It's frustrating that we don’t have standardized ways to do basic initial research because that would improve comparisons of data between labs and also accelerate things forward. So based on the two studies above and also historical data on other interventions I created a list to try to give a bigger picture of how things may be related to each other. I’m very curious to see research on the combination Rapamycin (42 ppm) + Acarbose (1000 ppm) + Trametinib (1.44ppm) and when treatment is started at 16 months of age in UM-HET3 mice. It would also be very interesting to get safety and beneficial data on low dose of Trametinib in humans because that data will most likely differ from how things are when treating disease with high doses.

Can't agree more. Good speech! Treating #aging as #medical #condition

Meet us at Aging Research & Drug Discovery Meeting Let's combat aging together! Our #pitch is scheduled for August 29th, 2024 during https://lnkd.in/dmRE-qJv #longevity #aging #drugdevelopment #conference #lifespan #biotech #deeptech #agetech #AI 

Rejuvenation of memory and DNA methylation in the hippocampus of 2 year old rats via Yamanaka factor adenovirus gene therapy. #GeneTherapy #Neuroscience #Aging Rudy Goya (2024) Cognitive rejuvenation in old rats by hippocampal OSKM gene therapy. GeroScience. https://lnkd.in/d3i2Psmq